NCT05168748View on ClinicalTrials.gov

CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 24, 2023

Primary Completion Date

August 13, 2026

Study Completion Date

August 13, 2026

Conditions
Acute Lymphoblastic Leukemia
Interventions
DRUG

IMJ995 single agent

Single intravenous administration of IMJ995

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY